<DOC>
	<DOC>NCT00195442</DOC>
	<brief_summary>The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.</brief_summary>
	<brief_title>Study Evaluating Refacto For Pharmacovigilance</brief_title>
	<detailed_description>Non-interventional study: subjects to be selected according to the usual clinical practice of their physician</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Proven diagnosis of Hemophilia A Contraindications according to Summary of Product Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>